AEON Biopharma Announces Topline Results From Phase 2 Trial Of ABP-450 For The Preventive Treatment Of Episodic Migraine
Portfolio Pulse from Benzinga Newsdesk
AEON Biopharma announced topline results from its Phase 2 trial of ABP-450 for the preventive treatment of episodic migraine. The treatment showed a positive effect but did not meet statistical significance versus placebo due to a higher-than-expected placebo response. However, the study demonstrated statistical significance on multiple secondary and exploratory endpoints. The data supports the decision to advance into Phase 3, anticipated in 2H 2024. An ongoing Phase 2 trial for the preventive treatment of chronic migraine has enrolled over 430 subjects, with enrollment completion expected in Q4 2023 and topline data in 2H 2024.
October 19, 2023 | 8:08 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
AEON Biopharma's Phase 2 trial of ABP-450 showed positive results but did not meet statistical significance versus placebo. The company plans to advance into Phase 3 in 2H 2024.
The news is directly related to AEON Biopharma and its product ABP-450. While the results did not meet statistical significance versus placebo, the company is confident enough to proceed to Phase 3. This could potentially have a neutral to positive impact on the company's stock in the short term as it shows progress in their product development, but the lack of statistical significance might temper investor enthusiasm.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100